Unitree Robotics filed for a $610M IPO on Shanghai's Star Market with explosive growth (674% net profit surge, 335% revenue growth in 2025), positioning itself as a commercially validated humanoid and quadruped robot maker.
Chinese humanoid robot maker Unitree Robotics filed to raise 4.2 billion yuan — roughly $610 million — on Shanghai's Star Market last week, per its prospectus. The numbers are not the part worth watching.
Revenue last year was 1.71 billion yuan, up 335 percent from the year before. Adjusted net profit was 600 million yuan, up 674 percent. Those are the numbers that make the pitch work: a Chinese robotics company with genuine commercial traction, raising public capital at the moment the U.S. government is trying to write it out of the world's largest single-buyer market.
The American Security Robotics Act, introduced by Senators Tom Cotton and Chuck Schumer on March 26, would prohibit federal agencies from procuring or operating unmanned ground vehicles manufactured by foreign adversaries — specifically naming China. The bill cites documented security concerns: backdoor access pathways, telemetry exfiltration risks, and the ability to remotely control devices operating inside U.S. facilities. It is not yet law. It is also not a hypothetical.
The timing is not lost on anyone following this space. Unitree's filing comes as the company is actively seeking to expand internationally — its Go2 quadruped and Ali-1 humanoid are already in use at research institutions and logistics facilities outside China. The prospectus will determine whether U.S. exposure is material to the valuation story. For a company raising $610 million on the prospect of global commercial expansion, a congressional ban on sales to the U.S. federal government is not a rounding error.
Agibot, a Shanghai-based rival, is targeting a separate listing on the Hong Kong Stock Exchange in the third quarter of 2026, per Reuters, with a valuation target of $5.1 billion to $6.4 billion. Both companies are raising public capital at the same moment U.S. policy is drawing a hard line on Chinese robotics procurement.
The U.S. restrictions are specific to federal procurement — universities, research labs, and commercial buyers are not the bill's target. But the trajectory is clear, and the signal to international buyers is not subtle: Chinese robotics companies seeking global market share are operating with one major government's procurement market effectively closed. How that changes the math for investors in a Shanghai IPO is the open question the prospectus has not answered.
The revenue growth is real. The policy headwind is also real. Whether the capital markets price one or both of those things correctly is where the story lives.